Global Aspergillosis Market Set for Steady Growth as Advanced Antifungal Therapies and Diagnostic Technologies Gain Momentum

Global Aspergillosis Market Overview

The Global Aspergillosis Market is witnessing steady expansion as healthcare systems strengthen the diagnosis and treatment of fungal infections, particularly among immunocompromised populations. According to Maximize Market Research, the market was valued at USD 3.99 billion in 2023 and is expected to grow at a CAGR of 3.7% from 2024 to 2030, reaching nearly USD 5.15 billion by 2030. Aspergillosis is a group of fungal infections caused by Aspergillus species and can range from allergic conditions to severe invasive infections. Rising numbers of immunocompromised patients, including individuals undergoing chemotherapy and organ transplantation, are increasing the need for effective antifungal treatment. The market is also benefiting from advances in next-generation sequencing, polymerase chain reaction testing, biomarker assays, point-of-care diagnostics, and laboratory automation. Growing antifungal resistance is simultaneously creating an urgent need for novel therapies with different mechanisms of action. Opportunities are emerging from preventive strategies, improved early diagnosis, novel antifungal drug development, and expanding access to specialized healthcare in emerging markets.

* Request Your Free Sample Copy: https://www.maximizemarketresearch.com/request-sample/233535/ 

US Market Trends and Investment

The United States remains a leading market for aspergillosis because of its advanced healthcare infrastructure, high disease awareness, specialized medical facilities, and substantial pharmaceutical research capabilities. During 2025, investment increasingly focused on developing new antifungal approaches for difficult-to-treat and drug-resistant fungal infections. SCYNEXIS reported that the FDA lifted the clinical hold on ibrexafungerp and that its second-generation fungerp candidate, SCY-247, was advancing toward clinical development. The company also reported positive preclinical data for SCY-247 and planned Phase 1 data during 2025. Meanwhile, F2G continued developing oral olorofim, a novel antifungal candidate targeting serious fungal infections, including invasive aspergillosis; in June 2025, the company published Phase 2b results showing therapeutic responses in patients with limited or no treatment options. These developments highlight the growing U.S. focus on novel mechanisms, oral therapies, and treatments capable of addressing antifungal resistance.

Market Segmentation

According to the Maximize Market Research report, the Invasive Aspergillosis segment held the largest share of approximately 70% of the Global Aspergillosis Market in 2023. The segment is expected to continue growing at a 3.7% CAGR during the forecast period. Invasive aspergillosis primarily affects individuals with weakened immune systems and can become life-threatening when diagnosis and treatment are delayed. Its severity creates sustained demand for potent antifungal medicines, advanced diagnostic tools, and prolonged treatment strategies. The growing challenge of antifungal resistance further increases the need for innovative therapies and targeted diagnostic technologies, reinforcing the segment's dominant position.

Aspergillosis Market Key Players
1. North America

1. Pulmonomy Associates Inc (United States)
2. Scynexis Inc (United States)
3. Pfizer Inc (United States)
4. TFF Pharmaceuticals Inc (United States)
5. Thermo Fisher Scientific (United States)
6. Merck & Co (United States)
7. Pulmatrix (United States)
8. Lupin Pharmaceuticals (United States)
9. Aozeal (California)
10. Xellia Pharmaceuticals (Denmark)
11. Mylan Pharmaceuticals (United States)
12. Abbott Laboratories (United States)
13. Eli Lilly and Company (United States)
14. Johnson & Johnson Services, Inc. (United States)

2. Europe

1. GlaxoSmithKline (United Kingdom)
2. AstraZeneca (United Kingdom)
3. Novartis AG (Switzerland)
4. Bayer AG (Germany)
5. Hikma Pharmaceuticals (United Kingdom)
6. F2G Ltd (United Kingdom)
7. Pulmocide Ltd (United Kingdom)
8. Basilea Pharmaceutica Ltd (Switzerland)
9. Biosergen AS (Norway)

3. Asia Pacific

1. Cellix Bio Pvt Ltd (India)
2. AbGenics Life Sciences Pvt Ltd (India)
3. Rewine Pharmaceuticals (Inida)
4. Eugia Pharma (India)
5. Krishlar Pharmaceuticals (India)
6. Cipla (India)
7. Astellas Pharma (Japan)
8. Mayne Pharma Group Limited (Australia)
9. Takeda Pharmaceutical Company Ltd (Japan)

4. Middle East & Africa

1. Teva Pharmaceuticals (Israel)

Competitive Analysis

The Global Aspergillosis Market includes Pulmonomy Associates Inc., Scynexis Inc., Pfizer Inc., TFF Pharmaceuticals Inc., Thermo Fisher Scientific, Merck & Co., Pulmatrix, Lupin Pharmaceuticals, and other companies, according to the Maximize Market Research report. The supplied report lists these companies but does not provide a verified numerical ranking of the five largest companies by global market share. Therefore, the following companies are discussed as important market participants rather than claiming an unsupported top-five market-share ranking.

Scynexis Inc. is advancing next-generation antifungal research through SCY-247, a second-generation fungerp candidate designed to address difficult-to-treat fungal infections. In 2025, the company reported positive preclinical findings and advanced the program toward Phase 1 clinical evaluation.

F2G Ltd., although listed separately among the report's European market participants, is developing olorofim, a novel oral antifungal with a new mechanism of action. In 2025, Phase 2b results were published for patients with serious fungal infections, including invasive aspergillosis and azole-resistant Aspergillus infections. F2G and Shionogi are collaborating on development and commercialization, supporting potential expansion of treatment options.

Pfizer Inc. has established expertise in antifungal medicines, including CRESEMBA (isavuconazole), which is used for invasive aspergillosis. Its global commercialization strategy for CRESEMBA has expanded access across multiple international markets.

Pulmatrix is developing PUR1900, an inhaled formulation of itraconazole using its iSPERSE drug-delivery technology for pulmonary indications including allergic bronchopulmonary aspergillosis. Its collaboration with Cipla supports continued development and commercialization activities.

Thermo Fisher Scientific contributes to the market through diagnostic technologies and laboratory solutions. Continued improvements in molecular testing, laboratory automation, and analytical technologies can strengthen early detection and monitoring of Aspergillus infections.

Regional Analysis

United States: North America dominated the Global Aspergillosis Market with more than 40% share in 2023, according to Maximize Market Research. The region benefits from advanced healthcare infrastructure, high awareness, specialized treatment facilities, strong pharmaceutical R&D, and substantial investment in antifungal innovation.

United Kingdom: The UK is an important European market because of its advanced healthcare system, specialist infectious-disease capabilities, and pharmaceutical research ecosystem. The presence of companies such as F2G and Pulmocide further supports innovation in antifungal treatments.

Germany: Germany benefits from strong healthcare infrastructure, pharmaceutical research capabilities, and stringent regulatory standards. Demand for advanced diagnostics and antifungal medicines is supported by the country's focus on specialized medical treatment.

France: France represents an important European opportunity due to its developed healthcare system, pharmaceutical industry, and growing emphasis on effective management of serious fungal infections.

Japan: Japan has a well-developed pharmaceutical and healthcare sector and is home to Astellas Pharma and other companies involved in antifungal development. Collaboration between Japanese and international companies is also supporting the development of innovative antifungal therapies. F2G's collaboration with Shionogi is one example of this international development activity.

China: China offers significant long-term opportunities due to its large patient population, expanding healthcare infrastructure, and increasing access to advanced diagnostics and pharmaceutical treatments. Growing healthcare expenditure and improved disease awareness can support market expansion.

Conclusion

The Global Aspergillosis Market is expected to maintain steady growth as the healthcare industry addresses the increasing burden of serious fungal infections and growing antifungal resistance. The market's expansion from USD 3.99 billion in 2023 to nearly USD 5.15 billion by 2030 demonstrates sustained demand for improved treatment and diagnostic solutions. The most significant opportunities will come from novel antifungal mechanisms, rapid molecular diagnostics, improved drug-delivery systems, and therapies targeting resistant Aspergillus strains. Continued pharmaceutical R&D, strategic collaborations, and improved access to specialized care will be essential for strengthening treatment outcomes and supporting future market development.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com